Results of the Global Random Effects Model for Humoral and Cell-Mediated Immune Responses and the Global Reactogenicity Score After Each Dose of Adjuvanted Recombinant Zoster Vaccine
| Fixed Effects . | Estimatea . | SE . | T Value . | 95% CI . | P Value . | |
|---|---|---|---|---|---|---|
| 2.5% . | 97.5% . | |||||
| Humoral immune responses | ||||||
| (Intercept) | 4.743 | 0.110 | 43.193 | 4.523 | 4.955 | .000 |
| Log gE antibody levels prevaccination | 0.172 | 0.024 | 7.076 | .123 | .222 | .000 |
| Age | –0.005 | 0.001 | –4.072 | –.007 | –.002 | .000 |
| Maximum global score PD1 | –0.041 | 0.036 | –1.120 | –.114 | .042 | .263 |
| Maximum global score PD2 | 0.112 | 0.028 | 3.928 | .049 | .169 | .000 |
| Time (months since vaccination) | –0.259 | 0.003 | –88.268 | –.264 | –.254 | .000 |
| Cell-mediated immune responses | ||||||
| (Intercept) | 4.118 | 0.401 | 10.281 | 3.283 | 4.897 | .000 |
| Log gE-specific T-cell responses prevaccination | –0.039 | 0.050 | –0.797 | –.130 | .063 | .425 |
| Age | –0.011 | 0.006 | –1.988 | –.022 | .000 | .047 |
| Maximum global score PD1 | 0.097 | 0.181 | 0.535 | –.242 | .430 | .593 |
| Maximum global score PD2 | 0.230 | 0.129 | 1.790 | –.016 | .485 | .073 |
| Time (months since vaccination) | –0.223 | 0.025 | –9.026 | –.275 | –.172 | .000 |
| Fixed Effects . | Estimatea . | SE . | T Value . | 95% CI . | P Value . | |
|---|---|---|---|---|---|---|
| 2.5% . | 97.5% . | |||||
| Humoral immune responses | ||||||
| (Intercept) | 4.743 | 0.110 | 43.193 | 4.523 | 4.955 | .000 |
| Log gE antibody levels prevaccination | 0.172 | 0.024 | 7.076 | .123 | .222 | .000 |
| Age | –0.005 | 0.001 | –4.072 | –.007 | –.002 | .000 |
| Maximum global score PD1 | –0.041 | 0.036 | –1.120 | –.114 | .042 | .263 |
| Maximum global score PD2 | 0.112 | 0.028 | 3.928 | .049 | .169 | .000 |
| Time (months since vaccination) | –0.259 | 0.003 | –88.268 | –.264 | –.254 | .000 |
| Cell-mediated immune responses | ||||||
| (Intercept) | 4.118 | 0.401 | 10.281 | 3.283 | 4.897 | .000 |
| Log gE-specific T-cell responses prevaccination | –0.039 | 0.050 | –0.797 | –.130 | .063 | .425 |
| Age | –0.011 | 0.006 | –1.988 | –.022 | .000 | .047 |
| Maximum global score PD1 | 0.097 | 0.181 | 0.535 | –.242 | .430 | .593 |
| Maximum global score PD2 | 0.230 | 0.129 | 1.790 | –.016 | .485 | .073 |
| Time (months since vaccination) | –0.223 | 0.025 | –9.026 | –.275 | –.172 | .000 |
Model input parameters are presented in terms of the estimate of the effect size, standard error, 95% CI, and P value. The T value is the ratio between the estimate and the standard error
Abbreviations: CI, confidence interval; gE, glycoprotein E; PD1, post–dose 1; PD2, post–dose 2; SE, standard error.
The humoral and cell-mediated estimates refer to the estimated change in antibody concentration or CD4+ counts with each increase in reactogenicity score.
Results of the Global Random Effects Model for Humoral and Cell-Mediated Immune Responses and the Global Reactogenicity Score After Each Dose of Adjuvanted Recombinant Zoster Vaccine
| Fixed Effects . | Estimatea . | SE . | T Value . | 95% CI . | P Value . | |
|---|---|---|---|---|---|---|
| 2.5% . | 97.5% . | |||||
| Humoral immune responses | ||||||
| (Intercept) | 4.743 | 0.110 | 43.193 | 4.523 | 4.955 | .000 |
| Log gE antibody levels prevaccination | 0.172 | 0.024 | 7.076 | .123 | .222 | .000 |
| Age | –0.005 | 0.001 | –4.072 | –.007 | –.002 | .000 |
| Maximum global score PD1 | –0.041 | 0.036 | –1.120 | –.114 | .042 | .263 |
| Maximum global score PD2 | 0.112 | 0.028 | 3.928 | .049 | .169 | .000 |
| Time (months since vaccination) | –0.259 | 0.003 | –88.268 | –.264 | –.254 | .000 |
| Cell-mediated immune responses | ||||||
| (Intercept) | 4.118 | 0.401 | 10.281 | 3.283 | 4.897 | .000 |
| Log gE-specific T-cell responses prevaccination | –0.039 | 0.050 | –0.797 | –.130 | .063 | .425 |
| Age | –0.011 | 0.006 | –1.988 | –.022 | .000 | .047 |
| Maximum global score PD1 | 0.097 | 0.181 | 0.535 | –.242 | .430 | .593 |
| Maximum global score PD2 | 0.230 | 0.129 | 1.790 | –.016 | .485 | .073 |
| Time (months since vaccination) | –0.223 | 0.025 | –9.026 | –.275 | –.172 | .000 |
| Fixed Effects . | Estimatea . | SE . | T Value . | 95% CI . | P Value . | |
|---|---|---|---|---|---|---|
| 2.5% . | 97.5% . | |||||
| Humoral immune responses | ||||||
| (Intercept) | 4.743 | 0.110 | 43.193 | 4.523 | 4.955 | .000 |
| Log gE antibody levels prevaccination | 0.172 | 0.024 | 7.076 | .123 | .222 | .000 |
| Age | –0.005 | 0.001 | –4.072 | –.007 | –.002 | .000 |
| Maximum global score PD1 | –0.041 | 0.036 | –1.120 | –.114 | .042 | .263 |
| Maximum global score PD2 | 0.112 | 0.028 | 3.928 | .049 | .169 | .000 |
| Time (months since vaccination) | –0.259 | 0.003 | –88.268 | –.264 | –.254 | .000 |
| Cell-mediated immune responses | ||||||
| (Intercept) | 4.118 | 0.401 | 10.281 | 3.283 | 4.897 | .000 |
| Log gE-specific T-cell responses prevaccination | –0.039 | 0.050 | –0.797 | –.130 | .063 | .425 |
| Age | –0.011 | 0.006 | –1.988 | –.022 | .000 | .047 |
| Maximum global score PD1 | 0.097 | 0.181 | 0.535 | –.242 | .430 | .593 |
| Maximum global score PD2 | 0.230 | 0.129 | 1.790 | –.016 | .485 | .073 |
| Time (months since vaccination) | –0.223 | 0.025 | –9.026 | –.275 | –.172 | .000 |
Model input parameters are presented in terms of the estimate of the effect size, standard error, 95% CI, and P value. The T value is the ratio between the estimate and the standard error
Abbreviations: CI, confidence interval; gE, glycoprotein E; PD1, post–dose 1; PD2, post–dose 2; SE, standard error.
The humoral and cell-mediated estimates refer to the estimated change in antibody concentration or CD4+ counts with each increase in reactogenicity score.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
